奥拉西坦联合疏血通治疗原发性脑出血的临床研究

Clinical study of oxiracetam combined with shuxuetong in patients with primary intracranial hemorrhages

目的探讨奥拉西坦联合疏血通治疗原发性脑出血的临床疗效。方法将80例患者随机分为两组,治疗组44例,加用奥拉西坦和疏血通静脉滴注;对照组33例,加用胞磷胆碱钠静脉滴注,疗程均为21 d。以NIHSS计分评定神经功能缺失,以MMSE计分评定认知功能障碍,分析比较两组的治疗效果。结果治疗组NIHSS评分和MMSE评分与治疗前相比较P<0.01;与对照组相比较P<0.01。其疗效优于对照组。结论奥拉西坦联合疏血通治疗原发性脑出血疗效满意。

Objective To investigate the therapeutic efficacy of oxiracetam combined with shuxuetong in patients with primary intracranial hemorrhages. Methods Eighty cases with primary intracranial hemorrhages were randomly divided into two groups：44 cases were treated with oxiracetam combined with shuxuetong by intravenous infusing for 21days ;36 cases were the eonrtol group treated with eiticoline sodium by intravenous infusing for 21days. To evaluate neural dysfunction with the scores of NIHSS and cognitive dysfunction with the scores of MMSE. To analyze the therapeutic efficacy compared with the control group. Results In these two groups, all of the scores of NIHSS and MMSE after the therapy were better than those before the therapy. And there was statistical significance difference （P 〈0. 01） . The scores of NIHSS and MMSE and MMSE after the therapy were better in therapeutic group than those in the control group . And there was statistical significance difference between the two groups （ P 〈 0. 05 ） . Conclusion The therapeutic efficacy of oxiracetam combined with shuxuetong in treating patients with primary intracranial hemorrhages was well.